drugset / Trial / NCT00088218
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
RandomizedParallel-groupOpen-labelDiagnostic
Summary
The goal of this clinical research study is to study how effective treatments with clofarabine alone and clofarabine given in combination with ara-C are in the treatment of leukemia and high-risk myelodysplastic syndrome (MDS) in patients who are 60 years or older. The safety of these treatments will also be compared.
Timeline
- Start
- 2004-07
- Primary completion
- 2008-02
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clofarabine | Other / unclassified | 30 mg/m2 | Intravenous |
| Comparator | Cytarabine | Small molecule | 20 mg/m2 | Subcutaneous |